What a difference a day makes in biotech: Yesterday, antibiotics player Summit Therapeutics was riding high after an $8.8 million cash infusion from the U.S. Biomedical Advanced Research and Development Authority.
A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing, although don’t expect many megadeals.
Robert Bazemore, president and chief executive officer of Epizyme, called the accelerated approval of Tezverik “a landmark event” for people with epithelioid sarcoma, a soft-tissue cancer.
Kapoor was found guilty in May 2019 of orchestrating kickback schemes to encourage doctors to boost prescriptions of Subsys, a powerful pain killer.
Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that after further successful acute animal tests conducted earlier this week, a final design concept for the fully retrievable transfemoral trans-septal Tiara
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
Pharma and life sciences companies strengthen their leadership and boards with this week’s appointments.
Approximately one-quarter of patients who are prescribed opioids for chronic pain misuse them, with five to 10 percent developing an opioid use disorder or addiction. In a new study, researchers found that opioid dependence produced permanent changes in the brains of rats.